Analyst Ratings For Capricor Therapeutics (NASDAQ:CAPR)
Today, HC Wainwright reiterated its Buy rating on Capricor Therapeutics (NASDAQ:CAPR) with a price target of $8.60.
Some recent analyst ratings include
- 1/26/2018-HC Wainwright Reiterated Rating of Buy .
- 7/22/2017-Rodman & Renshaw Reiterated Rating of Buy.
Recent Insider Trading Activity For Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ:CAPR) has insider ownership of 28.50% and institutional ownership of 3.87%.
- On 5/9/2017 Louis Manzo, Director, bought 10,000 with an average share price of $3.10 per share and the total transaction amounting to $31,000.00.
- On 5/9/2017 Sinai Medical Center Cedars, Major Shareholder, bought 1,145,161 with an average share price of $3.10 per share and the total transaction amounting to $3,549,999.10.
- On 9/21/2016 Sinai Medical Center Cedars, Major Shareholder, bought 312,500 with an average share price of $3.20 per share and the total transaction amounting to $1,000,000.00.
- On 3/16/2016 Anthony Bergmann, VP, bought 2,030 with an average share price of $2.40 per share and the total transaction amounting to $4,872.00.
- On 3/16/2016 Karen Krasney, EVP, bought 4,060 with an average share price of $2.40 per share and the total transaction amounting to $9,744.00.
- On 3/16/2016 Leland Gershell, CFO, bought 2,100 with an average share price of $2.40 per share and the total transaction amounting to $5,040.00.
- On 3/16/2016 Linda Marban, CEO, bought 10,152 with an average share price of $2.40 per share and the total transaction amounting to $24,364.80.
Recent Trading Activity for Capricor Therapeutics (NASDAQ:CAPR)
Shares of Capricor Therapeutics closed the previous trading session at with 1.7899999618530273 shares trading hands.